In fiscal year 2025, Vaxcell-Bio Therapeutics (323990) reported revenue of 7.1 billion KRW.
Income Statement
| Year | Revenue | Op Profit | Net Income | Source |
|---|---|---|---|---|
| 2025 | 7.1 billion KRW | -15.5 billion KRW | -13.3 billion KRW | [source] |
| 2024 | 1.9 billion KRW | -15.0 billion KRW | -10.6 billion KRW | [source] |
| 2023 | 14 million KRW | -11.5 billion KRW | -10.3 billion KRW | [source] |
| 2022 | — | -8.2 billion KRW | -6.8 billion KRW | [source] |
| 2021 | — | -5.9 billion KRW | -4.8 billion KRW | [source] |
Balance Sheet
| Year | Total Assets | Total Liabilities | Total Equity | Source |
|---|---|---|---|---|
| 2025 | 66.9 billion KRW | 5.8 billion KRW | 61.1 billion KRW | [source] |
| 2024 | 76.9 billion KRW | 4.9 billion KRW | 72.0 billion KRW | [source] |
| 2023 | 85.0 billion KRW | 1.5 billion KRW | 83.5 billion KRW | [source] |
| 2022 | 24.2 billion KRW | 836 million KRW | 23.3 billion KRW | [source] |
| 2021 | 31.3 billion KRW | 1.2 billion KRW | 30.1 billion KRW | [source] |
This company has no revenue account in the DART financial statements. Industry-specific accounts such as insurance or interest income are not converted to revenue.